FIELD: medicine.
SUBSTANCE: invention relates to clinical laboratory diagnostics of lymphocytic lymphoma/chronic lymphocytic leukemia (CLL) using molecular genetic methods for simultaneously determining the level of expression of ribonucleic acids of different classes: microRNA and matrix RNA in a multiplex polymerase chain reaction in the "real time mode". The invention is a kit containing reagents for RNA isolation, reverse transcription reagents, including specific loop primers for microRNA, reagents for PCR, including optimally selected reaction mixtures for determining the expression of ABL1 mRNA and ROR1 mRNA, as well as miR-39 microRNA, miR-155 and miR-15a, Thermus aquaticus DNA polymerase, a positive control, a negative control, and a control marker for miRNA extraction efficiency. A distinctive feature of the kit is the use of original combinations of specific primers and fluorescently labeled DNA probes in three reaction mixtures, as well as the possibility of simultaneous determination of mRNA and microRNA. The first mixture includes the following primers: ABL-F, ABL-R, ROR-F, ROR-R and TaqMan probes: ABL-P, ROR-P with dyes. The second mixture contains the following primers: miR155-F, miR155-R, miR39-R, miR39-F and TaqMan probes: miR155-P, miR39-P with dyes. The third mixture contains the following primers: miR15a-F, miR15a-R. The invention allows simultaneous determination of the level of mRNA and microRNA in one analytical series using three test tubes with reaction mixtures. The technical result achieved by the claimed invention is a set of reagents for multiplex polymerase chain reaction, which allows to perform molecular genetic diagnosis of CLL using standard equipment of clinical diagnostic laboratories.
EFFECT: using the capabilities of the multiplex reaction mode leads to savings in the volume of the biological sample used, consumables and reduces the time of the analysis.
1 cl, 3 dwg, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING THE RADIOSENSITIVITY OF MALIGNANT RECTAL TUMOURS | 2020 |
|
RU2754154C1 |
METHOD FOR DIAGNOSING ACUTE LEUKEMIA AND KITS FOR ITS IMPLEMENTATION | 2021 |
|
RU2806591C2 |
TEST SYSTEM “miR-M-SCREEN” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH COLORECTAL CANCER BASED ON THE LEVEL OF miR-26a AND miR-143 MICRO-RNA IN BLOOD PLASMA | 2022 |
|
RU2786386C1 |
OLIGONUCLEOTIDES FOR DIAGNOSING EPILEPSY BY QUANTITATIVE PCR | 2023 |
|
RU2815113C1 |
ANALYTICAL SYSTEM FOR DIAGNOSING LUNG CANCER USING FREE AND CIRCULATING MICRO-RNAS ASSOCIATED WITH BLOOD CELLS | 2020 |
|
RU2755651C1 |
METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
METHOD OF DETECTING DNAJB1-PRKACA CHIMERIC TRANSCRIPT IN CLINICAL TISSUE SAMPLES FROM PATIENTS WITH FIBROLAMELLAR LIVER CARCINOMA USING REAL-TIME POLYMERASE CHAIN REACTION | 2023 |
|
RU2807306C1 |
BIOMARKERS OF TRAUMATIC BRAIN INJURY | 2017 |
|
RU2771757C2 |
REAGENT SET FOR ESTIMATING EFFICIENCY OF THERAPY WITH TYROSINE KINASE INHIBITORS AT Ph-POSITIVE NEOPLASMS AND ITS APPLICATION METHOD | 2020 |
|
RU2762356C2 |
METHOD OF PREDICTING THE DEVELOPMENT OF RELAPSE IN PATIENTS WITH HUMAN PAPILLOMAVIRUS AND NON-MUSCLE-INVASIVE BLADDER CANCER | 2022 |
|
RU2800265C1 |
Authors
Dates
2023-08-22—Published
2023-01-16—Filed